Dealing with cancer screening in the COVID-19 era
- PMID: 34406299
- DOI: 10.1590/1806-9282.67.Suppl1.20200889
Dealing with cancer screening in the COVID-19 era
Abstract
Objective: This article aims to alert health professionals for cancer screening in the face of the possibility of new waves of disease.
Methods: A narrative review was conducted through a search in MEDLINE, Lilacs, Chinese Biomedical Literature Database, and international medical societies publications.
Results: Breast cancer: in high-risk patients (confirmed familial cancer syndrome or with high-risk tools scores), clinicians should act according to usual recommendations; in average-risk individuals, consider screening with mammography with a longer time span (maximum of two years). Cervical cancer: women turning 25 years old who have already been immunized and with no previous Pap test can have the test postponed during the pandemic; if there is no previous dose of Human Papillomavirus vaccination, initiation of screening should be recommended following a more rigid approach for COVID prevention; in women over 30 years of age who have never participated in cervical screening, the first screening exam is also essential. Colorectal cancer: if the individual is at elevated risk for familial cancer, the screening with colonoscopy according to usual recommendations should be supported; if at average risk consider screening with Fecal Occult Blood Test. Prostate cancer: there is a trend to postpone routine prostate cancer screening until the pandemic subsides.
Conclusions: The decision to keep cancer screening must be discussed and individualized, considering the possibility of new waves of COVID-19.
Comment in
-
Cancer screening and COVID-19 pandemic.Rev Assoc Med Bras (1992). 2021 Dec;67(12):1748. doi: 10.1590/1806-9282.20210807. Rev Assoc Med Bras (1992). 2021. PMID: 34909943 No abstract available.
